Information on new prescription diet pills
Contrave is another hopeful weight loss drug candidate that has also achieved good results from its clinical testing phases. Contrave's maker is Orexigen Therapeutics out of California who are also responsible for the development of another anti-obesity drug named Empatic. Contrave is another mixture of two other drugs. The two drugs that create Contrave are Naltrexone and Bupropion. These two drugs are used for different things. Naltrexone is used to help fight addictions, particularly illegal drugs and alcohol. Bupropion is used to battle depression and also to help one stop smoking. As far as commonly referred to names, Naltrexone's trademark names come as Vivitrol® or Revia®. Bupropion's is better known as Wellbutrin® or Zyban®.
The dosages that have been used for clinical testing consist of the following: High dose 48mg of Naltrexone and 400mg of Bupropion. Mid dose is 32mg of Naltrexone and 400mg of Bupropion and Low dose is 16mg of Naltrexone and 400mg of Bupropion. The formula for Naltrexone was IR or immediate where as the Bupropion was SR or sustained release. As with Qnexa, one should never attempt to simply mix these drugs on their own, the formula releases most likely would be different and as a result could be very dangerous to ones health. Bupropion has been reported by some to reduce weight but the combination of Bupropion and Naltrexone in the special unique formulation has been proven to far out do any weight loss experienced by Bupropion. The FDA also has never approved Bupropion for the use of weight loss.
The Contrave diet medication like Qnexa exceeds the FDA requirement for a drug to be considered as an obesity fighting drug. In clinical tests, Contrave users tended to lose between 9% and 15% of their body mass. Some of the side effects reported have been mild to moderate cases of headaches, nausea and constipation. This is not meant to be an exhaustive list of side effects, rather some of the more common experienced ones.
As of March 31st 2010, Contrave was presented to the FDA for possible approval. If the FDA looks favorably upon it could be approved perhaps 10 months later. However a small error in their records keeping was found by the FDA shortly after it was submitted and as a result this could hold back any decision by a few weeks.
On December 7th of 2010 the FDA had its panel of doctor's vote on whether they would recommend that Contrave be approved for use. Their vote was 13 in favor, 7 against. As a result when the FDA deliberates on January 31st 2011 they will strongly take this vote into consideration. The FDA usually takes the recommendation outright from their panel but does have the right to decide otherwise. It turns out they rejected it but Contrave is not out of the picture just yet. The FDA and Orexigen Therapeutics reached an agreement and a study will be done with approximately 10,000 patients. The main issue here is to determine if Contrave poses a risk for major cardiovascular issues. This test will take around two years to complete. A plan is in place to start the trials by the 2nd quarter of 2012.